Current Challenges and Opportunities in Cost Effective and Affordable Biosimilars

27th October 2014

Category: Biosimilars

Tags: ,

By: Dr Daniel Galbraith, CSO,

Biosimilars challenge us in many ways but for me these issues can be divided into those for a scientist, those for the industry and those for the patient. In my job, as a CSO working in Contract Research Organization, I have found Biosimilars have forced us to better understand the biological aspects of these drugs. More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.